Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celltrion, Inc.
Celltrion has received a positive opinion from the CHMP for five additional indications for its Remsima SC biosimilar, expanding the scope of the subcutaneous infliximab product that was launched earlier this year.
EU approval is likely for the eight medicines that got the thumbs up this week from the European Medicines Agency's drug evaluation committee, the CHMP. The panel held fire on one product it had been considering and also issued its first rejection of 2020.
Coronavirus Update: Vaccine Developers Search For Exposed Patients, Celltrion's Infliximab Shows Promise
As a handful of frontrunners prepare to start Phase III trials of their COVID-19 vaccine candidates, enrolling patients who are likely to be exposed to the virus is of crucial importance.
Sun has inked another commercial partnership to bring psoriasis drug Ilumya to countries outside India, this time teaming with Hikma in the MENA region.
- Other Names / Subsidiaries
- Bio CDMO
- Celltrion Healthcare Hungary Kft